Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

A new decade of disruption: meeting the biosimilar challgenge

Ten years after biosimilars first rocked their boat, how will biologics stay competitive?

Kiadis Pharma appoints new chief operations officer

Jan Feijen joins the company from Janssen

- PMLiVE

Ipsen appoints new executive vp and president, primary care

Benoit Hennion will also join the executive leadership team

Bring some #LucidLife to your medical education programmes

Meet Madeleine, an Account Director.Madeleine understands the importance of improving patient outcomes and has played a pivotal part in developing many of our award-winning behaviour-change programmes.Our people are our biggest...

Lucid Group Communications Limited

Empowering nurses to transform patient care

As Sustainability and Transformation Plans (STPs) turn to action across England, Page & Page’s Communications Director Cori Hollenbach explores whether healthcare companies are considering the influence nurses can have on...

Page & Page Health

- PMLiVE

Xarelto beats aspirin for recurrent blood clots

Trial shows the NOAC reduces the risk of blood clots by 74%

- PMLiVE

Making digital health personal

What makes a tool successfully support adherence and deliver value-based care?

- PMLiVE

Repatha outcomes data “less than stellar”

Analysts underwhelmed by latest results on Amgen's drug despite it seeing some improvements

- PMLiVE

Kris Barker joins J+D Consulting

He moves from Adelphi Research UK to take up senior consultant role

- PMLiVE

Clinerion appoints new regional head

Bariş Erdoğan takes up new role at the clinical trial data firm

Patient Centricity: Turning Rhetoric into Reality

Live webinar: Thursday 30th March 10:00 EDT / 15:00 BST / 16:00 CEST

Inizio

AstraZeneca AZ

FDA turns down AZ’s ZS-9 once again on manufacturing issues

The regulator says it can resubmit the application once deficiencies are tackled

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links